DIABETES MELLITUS: INSULIN SECRETION AND REGULATION
Keywords:
diabetes mellitus, insulin, beta-cell, glucose metabolism, endocrine system, hormone regulationAbstract
This article examines the pathogenesis of diabetes mellitus, mechanisms of insulin hormone secretion, and its regulatory processes in the organism. The physiological foundations of insulin secretion, beta-cell function, glucose homeostasis regulation, and metabolic disorders occurring in various forms of diabetes are studied. The research demonstrates the importance of modern medical approaches and insulin therapy in diabetes management.
References
American Diabetes Association (2023). Standards of Medical Care in Diabetes-2023. Diabetes Care, 46(Supplement 1), S1-S291.
Kasper D.L., Fauci A.S., Hauser S.L., Longo D.L., Jameson J.L., Loscalzo J. (2018). Harrison's Principles of Internal Medicine. 20th Edition. McGraw-Hill Education.
Kahn S.E., Cooper M.E., Del Prato S. (2014). Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, 383(9922), 1068-1083.
Rorsman P., Braun M. (2013). Regulation of insulin secretion in human pancreatic islets. Annual Review of Physiology, 75, 155-179.
DeFronzo R.A., Ferrannini E., Groop L., Henry R.R., Herman W.H., Holst J.J., et al. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1, 15019.
Atkinson M.A., Eisenbarth G.S., Michels A.W. (2014). Type 1 diabetes. Lancet, 383(9911), 69-82.
Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.
Skyler J.S., Bakris G.L., Bonifacio E., Darsow T., Eckel R.H., Groop L., et al. (2017). Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes, 66(2), 241-255.
Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu C., et al. (2020). 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 43(2), 487-493.
Nathan D.M., DCCT/EDIC Research Group (2014). The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care, 37(1), 9-16.
Herold K.C., Bundy B.N., Long S.A., Bluestone J.A., DiMeglio L.A., Dufort M.J., et al. (2019). An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. New England Journal of Medicine, 381(7), 603-613.
Azerbaijan
Türkiye
Uzbekistan
Kazakhstan
Turkmenistan
Kyrgyzstan
Republic of Korea
Japan
India
United States of America
Kosovo